Life sciences and healthcare industry leaders invest in Tact.ai
Torys acted as counsel to Sixty Degree Capital an investor with a team that included Cheryl Reicin and Shane Thomas (corporate/life sciences).
On September 20, 2021, Tact.ai announced a new round of equity financing totaling US$33 million that included investments from Novartis (dRx Capital), Lilly and McKesson Ventures. Existing investors including Microsoft's M12 and Salesforce Ventures also participated in the round. These investments highlight the ever-growing demand for hybrid engagement, recognizing how Tact helps the life sciences industry — including pharmaceutical, medical device and biotech companies — to work more effectively with healthcare professionals (HCPs) and healthcare organizations.
Further information can be found on PR Newswire’s website.
Tact.ai is on a mission to help life science organizations nurture meaningful customer engagement through our human-friendly software. Thier AI-powered engagement platform empowers field teams to work with their customers in new ways to drive better outcomes.